Beijing Innocare Pharma Tech Co., Ltd.

This study tests an experimental drug called ICP-248 in 75 adults whose mantle cell lymphoma has returned or stopped responding to prior therapy. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also monitor side effects and how long any ben…

This study tests a new drug called ICP-B208 in about 539 people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants must be 18-75, have failed pr…

This study tests an oral medication called ICP-488 for people with cutaneous lupus erythematosus (CLE), a condition that causes painful skin rashes and lesions. About 105 adults aged 18–75 with moderate-to-severe CLE will receive either the drug or a placebo for 16 weeks. The mai…

This study tests an experimental pill called ICP-332 in 344 adults with moderate to severe chronic spontaneous urticaria (hives) that antihistamines can't control. Participants will take the drug or a placebo for 12 or 24 weeks. The main goal is to see if the drug reduces itching…

This early-phase study tests a new drug (ICP-248) combined with a standard medicine (azacitidine) in people with acute myeloid leukemia or myelodysplastic syndromes. The goal is to find a safe dose and see if the combo helps control the disease. About 266 adults who have not resp…

This Phase 3 trial tests an oral drug called ICP-488 in 383 adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive either the drug or a placebo for 16 weeks. The main goal is to see if the drug can significantly clear or nearly clear the sk…

This phase 2 trial tests an experimental oral drug called ICP-332 against a placebo in 172 adults with moderate-to-severe plaque psoriasis. Participants take the drug or placebo daily for 12 weeks. The main goal is to see if at least 75% of skin symptoms improve. If it works, ICP…

This study tests a new drug combination (ICP-248 plus orelabrutinib) in people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if the combination is safe and tolerable. About 226 adults aged 18 to 80 with measurable disease and a need…

This phase 3 trial tests whether a combination of orelabrutinib and rituximab works better than lenalidomide plus rituximab for people with marginal zone lymphoma that has come back or not responded to treatment. About 324 adults will be randomly assigned to one of the two treatm…

This study tests an experimental drug called ICP-723 in people with advanced solid tumors or primary central nervous system tumors that have a specific genetic change called NTRK fusion. The drug is taken as a tablet once daily. The main goal is to see how many patients' tumors s…

This early-stage study tests an experimental drug called ICP-248, taken as a pill, for people with certain blood cancers (like leukemia or lymphoma). The drug is given alone or with another drug, orelabrutinib. The main goals are to check safety, find the right dose, and see if i…

This Phase 3 trial tests an oral drug called ICP-332 for people with moderate to severe atopic dermatitis (eczema) who haven't gotten enough relief from topical treatments. About 552 adults will receive either the drug or a placebo pill for several weeks. Researchers will measure…

This study tests an experimental oral drug called ICP-723 in people with advanced solid tumors that cannot be removed by surgery. The trial includes both adults and adolescents (ages 12 and up). The main goals are to check the drug's safety, find the best dose, and see if it can …

This study tests an experimental drug called ICP-332 for people with prurigo nodularis, a skin condition causing many intensely itchy bumps. About 135 adults will receive either the drug or a placebo to see if it reduces itching and clears the bumps over 16 weeks. The goal is to …

This early-phase trial is testing the safety and tolerability of a new drug called ICP-538 in 104 healthy adults. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and how the drug moves through the body. The goal is to gather b…